Modifies provisions relating to alternative therapies and treatments, including psilocybin

HB 951 legalizes personal therapeutic use of psilocybin for adults 21+ with specific conditions (end-of-life care, PTSD, major depression, substance use disorders, or other FDA-registered clinical trial-approved conditions). It requires documentation from a physician in a bona fide patient relationship, a trained facilitator (with 30+ hours of approved training), lab testing of psilocybin, and limits use to 150mg annually. The bill protects users, facilitators, and providers from legal penalties for compliant use and ensures confidentiality of patient information. It does not permit commercial sales or public use, focusing solely on regulated personal therapeutic applications.